These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 32053529)

  • 1. Efficacy and Safety of Monoclonal Antibodies Against Clostridioides difficile Toxins for Prevention of Recurrent Clostridioides difficile Infection: A Systematic Review and Meta-Analysis.
    Akiyama S; Yamada A; Komaki Y; Komaki F; Micic D; Sakuraba A
    J Clin Gastroenterol; 2021 Jan; 55(1):43-51. PubMed ID: 32053529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Bezlotoxumab in Trial Participants Infected With Clostridioides difficile Strain BI Associated With Poor Outcomes.
    Johnson S; Citron DM; Gerding DN; Wilcox MH; Goldstein EJC; Sambol SP; Best EL; Eves K; Jensen E; Dorr MB
    Clin Infect Dis; 2021 Nov; 73(9):e2616-e2624. PubMed ID: 32735653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: 12-Month Observational Data From the Randomized Phase III Trial, MODIFY II.
    Goldstein EJC; Citron DM; Gerding DN; Wilcox MH; Gabryelski L; Pedley A; Zeng Z; Dorr MB
    Clin Infect Dis; 2020 Aug; 71(4):1102-1105. PubMed ID: 31883370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of recurrent Clostridioides difficile infection: A systematic review of randomized controlled trials.
    Madoff SE; Urquiaga M; Alonso CD; Kelly CP
    Anaerobe; 2020 Feb; 61():102098. PubMed ID: 31493500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection.
    Wilcox MH; Gerding DN; Poxton IR; Kelly C; Nathan R; Birch T; Cornely OA; Rahav G; Bouza E; Lee C; Jenkin G; Jensen W; Kim YS; Yoshida J; Gabryelski L; Pedley A; Eves K; Tipping R; Guris D; Kartsonis N; Dorr MB;
    N Engl J Med; 2017 Jan; 376(4):305-317. PubMed ID: 28121498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, Safety, and Cost-effectiveness of Bezlotoxumab in Preventing Recurrent Clostridioides difficile Infection : Systematic Review and Meta-analysis.
    Mohamed MFH; Ward C; Beran A; Abdallah MA; Asemota J; Kelly CR
    J Clin Gastroenterol; 2024 Apr; 58(4):389-401. PubMed ID: 37395627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Endogenous Clostridioides difficile Toxin Antibodies on Recurrence of C. difficile Infection.
    Kelly CP; Poxton IR; Shen J; Wilcox MH; Gerding DN; Zhao X; Laterza OF; Railkar R; Guris D; Dorr MB
    Clin Infect Dis; 2020 Jun; 71(1):81-86. PubMed ID: 31628838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of C. difficile infection-related outcomes in European participants in the bezlotoxumab MODIFY I and II trials.
    Bouza E; Cornely OA; Ramos-Martinez A; Plesniak R; Ellison MC; Hanson ME; Dorr MB
    Eur J Clin Microbiol Infect Dis; 2020 Oct; 39(10):1933-1939. PubMed ID: 32504314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic Association Reveals Protection against Recurrence of
    Shen J; Mehrotra DV; Dorr MB; Zeng Z; Li J; Xu X; Nickle D; Holzinger ER; Chhibber A; Wilcox MH; Blanchard RL; Shaw PM
    mSphere; 2020 May; 5(3):. PubMed ID: 32376702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Add-on interventions for the prevention of recurrent Clostridioides Difficile infection: A systematic review and network meta-analysis.
    Paschos P; Ioakim K; Malandris K; Koukoufiki A; Nayfeh T; Akriviadis E; Tsapas A; Bekiari E
    Anaerobe; 2021 Oct; 71():102441. PubMed ID: 34454094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of bezlotoxumab for prevention of recurrent Clostridium difficile infection (CDI) in Japanese patients.
    Mikamo H; Aoyama N; Sawata M; Fujimoto G; Dorr MB; Yoshinari T
    J Infect Chemother; 2018 Feb; 24(2):123-129. PubMed ID: 29097028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Comparison of Bezlotoxumab to Standard of Care Therapy for Prevention of Recurrent Clostridioides difficile Infection in Patients at High Risk for Recurrence.
    Johnson TM; Molina KC; Howard AH; Schwarz K; Allen L; Huang M; Bajrovic V; Miller MA
    Clin Infect Dis; 2022 May; 74(9):1572-1578. PubMed ID: 34665248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of bezlotoxumab in preventing the recurrence of Clostridioides difficile infection: an Italian multicenter cohort study.
    Meschiari M; Cozzi-Lepri A; Cervo A; Granata G; Rogati C; Franceschini E; Casolari S; Tatarelli P; Giacobbe DR; Bassetti M; Pinna SM; De Rosa FG; Barchiesi F; Canovari B; Lorusso C; Russo G; Cenderello G; Cascio A; Petrosillo N; Mussini C
    Int J Infect Dis; 2023 Jun; 131():147-154. PubMed ID: 37030653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence.
    Gerding DN; Kelly CP; Rahav G; Lee C; Dubberke ER; Kumar PN; Yacyshyn B; Kao D; Eves K; Ellison MC; Hanson ME; Guris D; Dorr MB
    Clin Infect Dis; 2018 Aug; 67(5):649-656. PubMed ID: 29538686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing the efficacy and safety of faecal microbiota transplantation with bezlotoxumab in reducing the risk of recurrent
    Alhifany AA; Almutairi AR; Almangour TA; Shahbar AN; Abraham I; Alessa M; Alnezary FS; Cheema E
    BMJ Open; 2019 Nov; 9(11):e031145. PubMed ID: 31699731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Monoclonal Antitoxin Antibodies (Actoxumab-Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with
    Džunková M; D'Auria G; Xu H; Huang J; Duan Y; Moya A; Kelly CP; Chen X
    Front Cell Infect Microbiol; 2016; 6():119. PubMed ID: 27757389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Actoxumab + bezlotoxumab combination: what promise for Clostridium difficile treatment?
    Posteraro B; Pea F; Masucci L; Posteraro P; Sanguinetti M
    Expert Opin Biol Ther; 2018 Apr; 18(4):469-476. PubMed ID: 29534621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bezlotoxumab in the treatment of Clostridioides difficile infections: a real-life experience.
    Olmedo M; Kestler M; Valerio M; Padilla B; Rodríguez González C; Chamarro E; Machado M; Álvarez-Uría A; Alcalá L; Muñoz P; Bouza E
    Rev Esp Quimioter; 2022 Jun; 35(3):279-283. PubMed ID: 35279984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AAV-mediated delivery of actoxumab and bezlotoxumab results in serum and mucosal antibody concentrations that provide protection from C. difficile toxin challenge.
    Guilleman MM; Stevens BAY; Van Lieshout LP; Rghei AD; Pei Y; Santry LA; Thompson B; Wootton SK
    Gene Ther; 2023 May; 30(5):455-462. PubMed ID: 33608675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bezlotoxumab: Could This be the Answer for Clostridium difficile Recurrence?
    Chapin RW; Lee T; McCoy C; Alonso CD; Mahoney MV
    Ann Pharmacother; 2017 Sep; 51(9):804-810. PubMed ID: 28480750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.